

Learner Notification

Total Health Conferences

OneOncology Physician Leadership Conference 2022

November 11, 2022 - November 13, 2022

Nashville, TN

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. If you need MOC credit, you also need to pass a posttest with a score of at least 80%. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferences. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation Statement

Amedco LLC designates this live activity for a maximum of 15.50 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists and Pharmacy Technicians

Amedco LLC designates this activity for a maximum of 15.50 knowledge-based CPE contact hours.

Nurses (ANCC) Credit Designation Statement

Amedco LLC designates this activity for a maximum of 15.50 ANCC contact hours.

American Board of Internal Medicine (ABIM) MOC



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME

for the purpose of granting ABIM MOC credit.

You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.

Objectives - After Attending This Program You Should Be Able To

1. increased understanding of value-based care, challenges of changes in oncology care
2. Understand the complexity of both tumor and cfDNA testing in managing cancer patients and screening for early cancer
3. Updates on advances in lung, breast, and GI tumors

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

| Name | Commercial Interest:Relationship |
|-------------------|---|
| Duncan Allen | NA |
| Edward Arrowsmith | NA |
| Jesus Berdeja | NA |
| Michael Berger | Eli Lilly, AstraZeneca:Consultant |
| Adam Boehler | NA |
| Mary Darden | NA |
| Dana DeMoss | NA |
| William DiScipio | NA |
| David Eagle | Glaxo Smith Kline, Novartis, Abbvie, Merck, Johnson and Johnson, Gilead:Stock Shareholder |
| kenzie gancsos | NA |
| Chris Garabedian | Sermonix, Avenge Bio, Astria Therapeutics:Stock Shareholder Landos Biopharma, Forge Biologics, AsclepiX Therapeutics, Zucara Therapeutics, Cerevasc:Corporate Board Member |
| Benjamin Garmezy | NA |
| Erika Hamilton | Abbvie, Acerta Pharma, Accutar Biotechnology , ADC Therapeutics, AKESOBIO Australia, Amgen , Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx:Research Grant Site Principal Investigator |
| David Hsu | NA |
| W. Clay Jackson | Sage, Otsuka:Scientific/Medical Advisory Board Member AbbVie, Acerta:Research Grant Site Principal Investigator, Research Funding AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Calithera Biosciences, Carisma Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunocore, Impact, Incyte, Janssen, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Merus, Mirati Therapeutics, Neolmmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals / Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax |
| Melissa Johnson | |

| | |
|-------------------|---|
| | Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, Y-mAbs Therapeutics II. CONSULTING/ADVISORY ROLE AbbVie, Amgen, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, EMD Serono, G1 Therapeutics, Genentech / Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Ideaya Biosciences, iTeos, Janssen, Lilly, Merck, Mirati Therapeutics, Molecular Axion, Novartis, Oncorus, Regeneron Pharmaceuticals, Ribon Therapeutics, Sanofi-Aventis, Turning Point Therapeutics, VBL Therapeutics |
| Kevin Kalinsky | Grail, Pfizer, Array BioPharma:Research Grant Overall Principal Investigator Eli-Lilly, Pfizer, Novartis, Eisai, AstraZeneca, Immunomedics, Merck, Seattle Genetics, and CycloCell:Consultant |
| Ogi Kavazovic | NA |
| Meredith McKean | Aadi Biosciences , Accutar Biotechnology, Alpine Immune Sciences , Arcus Biosciences, Arvinas, Ascentage Pharma Group, Astellas, Bayer, Bicycle Therapeutics, BioMed Valley Discoveries, BioNTech, Dragonfly Therapeutics :Research Grant Site Principal Investigator, Research Funding Aadi Biosciences, Accutar Biotechnology, Alpine Immune Sciences, Arcus Biosciences, Arvinas, Ascentage Pharma Group, Astellas, Bayer, Bicycle Therapeutics, BioMed Valley Discoveries, BioNTech, Dragonfly Therapeutics, EMD Serono, Epizyme, Erasca, Exelixis, Foghorn Therapeutics, G1 Therapeutics, Genentech, Gilead Sciences, GlaxoSmithKline, IDEAYA Biosciences, Ikena Oncology, ImmVira Pharma, Infinity Pharmaceuticals, Jacobio Pharmaceuticals, Kechow Pharma, Kezar Life Sciences, Kinnate BioPharma, MedImmune, Mereo BioPharma, Metabomed, Moderna, NBE Therapeutics, Nektar, Novartis, OncoC4, Oncorus, PACT Pharma, Pfizer, Plexikon, Poseida, Prelude Therapeutics, Pyramid Biosciences, Regeneron, Sapience Therapeutics, Scholar Rock, Seattle Genetics, Synthrox, Takeda Pharmaceuticals, Tenebio, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, TopAlliance Biosciences, Xilio, Consulting/Advisory Role Astellas Pharma, AstraZeneca, BicycleTX Limited, Castle Biosciences, Eisai, Ideaya Biosciences, iTeos, Moderna, Pfizer |
| Loretta Nastoupil | ADC Therapeutics, Morphosys:Scientific/Medical Advisory Board Member BMS, Caribou Biosciences, Epizyme, Genentech, Genmab, Janssen, IGM Biosciences, Novartis, Takeda:Research Grant Site Principal Investigator |
| Rachel Parker | NA |
| kavita patel | Everside Health :Corporate Board Member |
| Jeff Patton | NA |
| Meredith Pelster | Arcus Biosciences , Astellas, Codiak Biosciences , CytomX, Eisai, Gritstone Oncology, HiberCell, Immune-Onc Therapeutics , OncXerna Therapeutics , Surface Oncology, SQZ Biotechnologies, TransThera Sciences :Research Grant Site Principal Investigator, I, Research Funding, Arcus Biosciences, Astellas, Codiak Biosciences, CytomX, Eisai, Gritstone Oncology, HiberCell, Immune-Onc Therapeutics, OncXerna Therapeutics, Surface Oncology, SQZ Biotechnologies, TransThera Sciences, ZielBio II, Consulting/Advisory Role AstraZeneca, Bayer, Novartis, Pfizer, SeaGen |
| Jason Porter | Bristol Myers Squibb:Speakers Bureau Bristol Myers Squibb, Novartis, Jazz Pharmaceuticals, Astra Zeneca:Scientific/Medical Advisory Board Member |
| James Salwitz | NA |
| | Aeglea Biotherapeutics, Agios, Amgen, AnHeart Therapeutics, Apollomics, Arcus, Arrys |

| | |
|-----------------|--|
| David Spigel | <p>Therapeutics , Ascendis Pharma, Astellas, AstraZeneca, Bayer, BeiGene:Research Grant Site Principal Investigator Research Funding Aeglea Biotherapeutics, Agios, Amgen, AnHeart Therapeutics, Apollomics, Arcus, Arrys Therapeutics, Ascendis Pharma, Astellas, AstraZeneca, Bayer, BeiGene, BIND Therapeutics, BioNTech RNA Pharmaceuticals, Blueprint Medicine, Boehringer-Ingelheim, Bristol-Myers Squibb, Calithera, Celgene, Celldex, Clovis, Cyteir Therapeutics, Daiichi Sankyo, Denovo Biopharma, Eisai, Elevation Oncology, Endeavor, Erasca, Faeth Therapeutics, FujiFilm Pharmaceuticals, G1 Therapeutics, Roche/Genentech, Gilead Sciences, GlaxoSmithKline, GRAIL, Hutchison MediPharma, ImClone Systems, Incyte, Ipsen, Janssen, Jazz Pharmaceuticals, Kronos Bio, Lilly, Loxo Oncology, Lyell Immunopharma, MacroGenics, MedImmune, Merck, Molecular Template, Nektar, Neon Therapeutics, Novartis, Novocure, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, SeaGen, Shenzhen Chipscreen Biosciences, SyntheKine, Taiho, Tango Therapeutics, Tarveda, Tesaro, Tizona Therapeutics, Transgene, UT Southwestern, Verastem, Zai Laboratory, Consulting/Advisory Role AstraZeneca, BeiGene, Bristol-Myers Squibb, Curio Science, EMD Serono, Evidera, GlaxoSmithKline, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, Lilly, Molecular Templates, Monte Rosa Therapeutics, Novartis, Novocure, Pfizer, Pyxis Oncology, Regeneron Pharmaceuticals, Roche/Genentech, Sanofi-Aventis</p> |
| Thomas Stricker | NA |
| Umang Swami | <p>Astellas, Seattle Genetics, Exelixis:Consultant Astellas, Seattle Genetics, Janssen, Exelixis:Research Grant Overall Principal Investigator, Astellas, Seattle Genetics, Exelixis, Imvax, Sanofi:Consultant Astellas, Seattle Genetics, Janssen, Exelixis:Research Grant Overall Principal Investigator</p> |
| Scott Tagawa | <p>Research support (to Weill Cornell Medicine): Sanofi, Medivation, Astellas, Janssen, Amgen, Lilly, Genentech, BMS, Inovio, AstraZeneca, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma, Paid Consultant: Sanofi, Medivation/Astellas, Janssen, Bayer, Eisai, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth, Alkido Pharma, Telix Pharma, Convergent Therapeutics, EMD Serono, Myovant, Patent: Biomarkers for sacituzumab govitecan therapy (Immunomedics / Gilead / Weill Cornell)</p> |

How to Get Your Certificate

1. Go to thc.cmecertificateonline.com
2. Click on the **OneOncology Physician Leadership Conference 2022** link.
3. For ABIM MOC click on the **One Oncology Physician Leadership Conference 2022 ABIM MOC** link.
4. Evaluate the meeting.
5. Print, download, or save your certificate for your records.
6. If you lose your certificate, or need help, go to help.cmecertificateonline.com